|
The Liver Meeting® 2009--AASLD's 60th Annual Meeting
Comparative Analysis of in Vivo Antiviral Effects and Induction of Interferon-Inducible Genes by Pegylated-interferon and albinterferon alfa-2b in HIV/HCV Co-infected Subjects. Poster 846 - November 1
Comparative Safety, Tolerability, Viral and Pharmacodynamic Efficacy of Pegylated-interferons and albinterferon alfa-2b in HIV/HCV Genotype-1 Infected Patients. Poster 870 - November 1
Efficacy and Safety of albinterferon alfa-2b in Combination with ribavirin in Treatment Naïve Patients with chronic hepatitis C genotype 1. Parallel Session 64 - November 1
Longitudinal Prospective Comparison of FibroSURE and FibroScan in Relation to Virologic Response in a Phase III study of albinterferon alfa-2b and ribavirin in Treatment Naïve CHC Patients. Poster 1084 - November 2
Efficacy and Safety Results of albinterferon alfa-2b in Combination with ribavirin in Treatment Naïve Subjects with Chronic Hepatitis C Genotype 2 or 3 . Poster 1567 - November 2
Sustained Virologic Response is Independently Associated with Improvement in Insulin Resistance in Genotype 1, but not Genotype 2/3, Chronic HCV Patients. Parallel Session 117 - November 2
Similar Rates of Interstitial Findings on Chest X-ray in HCV Patients Treated with albinterferon alfa-2b or peginterferon alfa-2a. Poster 1572 - November 3
Insulin Resistance and Hepatic Steatosis are Both Independently Associated with Advanced Hepatic Fibrosis in Chronic Hepatitis C Infection: Analysis of the ACHIEVE 1 and ACHIEVE 2/3 Cohorts. Poster 1622 - November 3
|
